HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Capitalizes As COVID Moves From Pandemic To Endemic

Executive Summary

Reckitt's OTC sales jumped 60% in the first half of 2022 as the milder omicron COVID-19 variant drove up demand for its leading cold and flu brands. This strong showing has led the firm to raise its full-year group sales guidance from 1-4% to 5-8%.

You may also be interested in...

US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall

House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.

Reckitt Sees Positive Signs For Cold & Flu Brands After Difficult First Half

Reckitt is seeing good signs in the US that cold and flu incidence is returning to more normal levels. However, the upswing came too late to materially impact first-half sales at its Health business, which posted turnover down 14%.

New Iron Source Granted EU Novel Food Approval

Ireland's Nemysis Limited has secured authorization from the European Commission to market in the EU a novel form of iron in supplements for both adults and children.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts